For us and for many other companies, the pandemic and global uncertainty have caused delays in some
prioritized projects. However, in combination with a dynamic capital market this has created a window
for us to review our overall funding. The opportunity to secure funding will enable full focus with
continued commercialization in priority markets and continued the research as soon as the market is
normalized again.